Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition

Cancer Research - United States
doi 10.1158/0008-5472.can-18-2003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability

Cancer Discovery
Oncology
2017English

Synergistic Induction of Cell Death in Haematological Malignancies by Combined Phosphoinositide-3-Kinase and BET Bromodomain Inhibition

British Journal of Haematology
Hematology
2015English

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins

English

BET Bromodomain Inhibition Enhances T Cell Persistence and Function in Adoptive Immunotherapy Models

Journal of Clinical Investigation
Medicine
2016English

BET Bromodomain Inhibition Releases the Mediator Complex From Select Cis-Regulatory Elements

Cell Reports
BiochemistryGeneticsMolecular Biology
2016English

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition

Cancer Research
Cancer ResearchOncology
2019English

BET Bromodomain Proteins Are Therapeutic Targets in CRPC

Cancer Discovery
Oncology
2014English

BET Bromodomain Inhibition Promotes De-Repression of TXNIP and Activation of ASK1-MAPK Pathway in Acute Myeloid Leukemia

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Inhibition of Bromodomain and Extra-Terminal Proteins (BET) as a Potential Therapeutic Approach in Haematological Malignancies: Emerging Preclinical and Clinical Evidence

Therapeutic Advances in Hematology
Hematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy